CTRI/2022/08/044617
Not yet recruiting
未知
Induction chemotherapy (TP Regimen) followed by concurrent chemoradiation in loco-regionally advanced nasopharyngeal carcinoma - A feasibility study
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: C119- Malignant neoplasm of nasopharynx,unspecified
- Sponsor
- Jawaharlal Institute of Postgraduate Medical Education and Research
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients will be eligible for inclusion in the study if they fulfilled all the following criteria:
- •Histologically confirmed, treatment\-naÃ?¯ve, Locoregionally advanced nasopharyngeal carcinoma patients (Stage III \& IVA\-, as per AJCC 8th Edition),
- •Aged between \>18 years\- 60 years of age,
- •Good performance status (ECOG\-0\-2\),
- •With adequate organ function at time of participation defined as: \-
- •1\.Hemoglobin ââ?°Â¥ 9 gm/dl; ANC ââ?°Â¥ 1500/mm3, Platelet Count ââ?°Â¥ 1,00,000/mm3
- •2\.Liver Function Test: Bilirubin ââ?°Â¤ 2x upper limit of normal (ULN), AST/ALT/ALP ââ?°Â¤ 2\.5 x ULN
- •3\.Renal Function Test: Creatinine ââ?°Â¤ 1\.5 ULN, Creatinine clearance ââ?°Â¥ 60ml/min.
- •Willing for treatment adherence, and willing for written informed consent
Exclusion Criteria
- •Any of the following\-
- •1\.Patients with previous history of anti\-cancer treatment, head and neck radiotherapy.
- •2\.Patients with uncontrolled comorbidities or life\-threatening diseases
- •3\.Pregnant patient
- •4\.Patients with distant metastases.
- •5\.Patients with synchronous primary tumor
- •6\.Evidence of moderate to severe hearing loss (as per Pure Tone Audiometry)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase III, multicenter, parallel-group randomized, controlled trial - ONCOCOL-01Cervical CancerMedDRA version: 21.1Level: LLTClassification code: 10008229Term: Cervical cancer Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10008236Term: Cervical cancer stage IV Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10008235Term: Cervical cancer stage III Class: 10029104Therapeutic area: Diseases [C] - Female Urogenital Diseases and Pregnancy Complications [C13]Therapeutic area: Phenomena and Processes [G] - Reproductive and Urinary Physiological Phenomena [G08]CTIS2024-513576-18-00Centre Hospitalier Universitaire De Toulouse310
Suspended
Phase 3
Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase III, multicenter, parallel-group randomized, controlled trial - ONCOCOL-012024-513576-18-00Centre Hospitalier Universitaire De Toulouse310
Active, not recruiting
Not Applicable
Induction chemotherapy followed by chemoradiation with cetuximab and cisplatin for inoperable squamous cell carcinoma of the head and neck.Inoperable squamous cell carcinoma of the head and neck.EUCTR2006-003381-33-SIInstitute of Oncology Ljubljana
Active, not recruiting
Not Applicable
Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumors of the oro- , hypopharynx and larynxTPF-C-HIT-Study - TPF-C-HITThe study is a phase II study of induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumors of the oro- , hypopharynx and laynx (TPF-C-HIT-Study)EUCTR2009-016489-10-DEniversity of Heidelberg
Completed
Phase 2
The phase II study of induction chemotherapy with cetuximab/S-1/low dose cisplatin for oral squamous cell carcinoma patientsoral squamous cell carcinomaJPRN-UMIN000014632The workshop of chemotherapy for oral cancer55